@article{3121941,
    title = "Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials",
    author = "Dimopoulos, M.A. and Moreau, P. and Iida, S. and Huang, S.-Y. and Takezako, N. and Chng, W.J. and Zahlten-Kumeli, A. and Sersch, M.A. and Li, J. and Huang, M. and Lee, J.H.",
    journal = "International Journal of Hematologic Oncology",
    year = "2019",
    volume = "110",
    number = "4",
    pages = "466-473",
    publisher = "Springer Tokyo",
    issn = "2045-1393, 2045-1407",
    doi = "10.1007/s12185-019-02704-z",
    keywords = "bortezomib;  carfilzomib;  dexamethasone;  lenalidomide, acute kidney failure;  adult;  aged;  Article;  Asian;  controlled study;  drug dose reduction;  drug efficacy;  drug safety;  drug withdrawal;  evaluation study;  female;  heart failure;  human;  hypertension;  major clinical study;  male;  multiple myeloma;  overall survival;  peripheral neuropathy;  progression free survival;  randomized controlled trial;  risk benefit analysis",
    abstract = "Carfilzomib is an irreversible proteasome inhibitor used for the treatment of relapsed and/or refractory multiple myeloma (RRMM). We evaluated the efficacy and safety of carfilzomib in subgroups of Asian patients in the randomized phase 3 ENDEAVOR and A.R.R.O.W. trials. In ENDEAVOR, patients received carfilzomib twice-weekly (56 mg/m2) plus dexamethasone (Kd; n = 56) or bortezomib plus dexamethasone (Vd; n = 57). In A.R.R.O.W., patients received carfilzomib once-weekly (70 mg/m2, n = 30) or twice-weekly (27 mg/m2, n = 15) plus dexamethasone. Median progression-free survival (PFS) among Asian patients in ENDEAVOR was longer with Kd than with Vd (14.9 versus 8.8 months; HR 0.599); the overall response rate (ORR) was 80.4% versus 70.2%. Median overall survival (Kd versus Vd) was 47.6 versus 38.8 months (HR 0.856). Median PFS among Asian patients in A.R.R.O.W. was longer for once-weekly versus twice-weekly Kd (16.0 versus 8.4 months; HR 0.628); ORR was 76.7% versus 53.3%. Rates of grade ≥ 3 adverse events were 89.1% (Kd) and 89.5% (Vd) in ENDEAVOR, and 76.6% (once-weekly Kd) versus 73.3% (twice-weekly Kd) in A.R.R.O.W. Overall, carfilzomib had a favorable benefit-risk profile across both dosing regimens [once-weekly (Kd 70 mg/m2) and twice-weekly (Kd 56 mg/m2)] in Asian patients with RRMM, which was consistent with the results of both parent studies. Trial registration ClinicalTrials.gov: NCT01568866, NCT02412878. © 2019, Japanese Society of Hematology."
}